QUEST DIAGNOSTICS INC
Close on Oct 19, 2026
- Market cap
- $26.31B
- P/E (TTM)
- 25.0
- Dividend yield
- –
Earnings
Next report expected Oct 20, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 23, 2026 | Before market open | $3.04B | $2.84 | $3.12 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 21, 2026 | Before market open | $2.90B | $2.24 | $2.50 |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 10, 2026 | Before market open | $2.81B | $2.18 | $2.42 |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 21, 2025 | Before market open | $2.82B | $2.16 | $2.60 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 22, 2025 | Before market open | $2.76B | $2.47 | $2.62 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 22, 2025 | Before market open | $2.65B | $1.94 | $2.21 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 30, 2025 | Before market open | $2.62B | $1.95 | $2.23 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 22, 2024 | Before market open | $2.49B | $1.99 | $2.30 |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 23, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 23, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 1, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Jul 23, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital expenditures | full year 2026 | $550.00M | Maintained |
| adjusted diluted EPSnon-GAAP | Full year 2026 | $11.05 to $11.25 | Raised |
| Reported diluted EPSGAAP | Full year 2026 | $9.97 to $10.17 | Raised |
| Cash provided by operations | full year 2026 | $1.80B | Raised |
| Net revenues increase | full year 2026 | 8.3% to 9.2% growth | Raised |
| Net revenues | Full year 2026 | $11.95B to $12.05B | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Quest Diagnostics filed with the SEC
Quest Diagnostics Reports Second Quarter 2026 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Prices $500 Million of Senior Notes
Other events · EX-99.1 to Form 8-K
Quest Diagnostics Reports First Quarter 2026 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Elects Timothy Wentworth, Former CEO of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results;
Results of operations · Other events · EX-99.1 to Form 8-K
Quest Diagnostics Increases Dividend 7.5% To $0.86 Per Quarter;
Results of operations · Other events · EX-99.2 to Form 8-K
PRESENTATION DATED JANUARY 12, 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Quest Diagnostics Reports Third Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Reports Second Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Reports First Quarter 2025 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Driving Sustainable Growth, Delivering Long-term Value
Regulation FD disclosure · EX-99.1 to Form 8-K
Karthik Kuppusamy, PhD Senior Vice President, Clinical Solutions
Regulation FD disclosure · EX-99.2 to Form 8-K
Improving Quality, Experiences, and Productivity
Regulation FD disclosure · EX-99.3 to Form 8-K
Quest Diagnostics to Highlight Strategic Priorities
Regulation FD disclosure · EX-99.1 to Form 8-K
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results;
Results of operations · Other events · EX-99.1 to Form 8-K
Quest Diagnostics Reports Third Quarter 2024 Financial Results;
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Prices $1.85 Billion of Senior Notes
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Quest Diagnostics Reports Second Quarter 2024 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics to Acquire LifeLabs
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quest Diagnostics Reports First Quarter 2024 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results;
Results of operations · Other events · EX-99.1 to Form 8-K
Quest Diagnostics Prices $750 Million of Senior Notes
Material agreement · Other events · EX-99.1 to Form 8-K
Quest Diagnostics Reports Third Quarter 2023 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Reports Second Quarter 2023 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Reports First Quarter 2023 Financial Results;
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Quest Diagnostics to Discuss Strategic
Regulation FD disclosure · EX-99.1 to Form 8-K
Driving Sustainable Growth in a Post-Pandemic World
Regulation FD disclosure · EX-99.2 to Form 8-K
The statements in the following presentations which are not historical facts may be forward looking
Regulation FD disclosure · EX-99.3 to Form 8-K
Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board
Other events · EX-99.1 to Form 8-K
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS;
Results of operations · Other events · EX-99.1 to Form 8-K
Quest Diagnostics Increases Dividend 7.6% To $0.71 Per Quarter;
Results of operations · Other events · EX-99.2 to Form 8-K
Quest Diagnostics Reports Third Quarter 2022 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Reports Second Quarter 2022 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Quest Diagnostics Names Sam Samad Executive Vice President and Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Quest Diagnostics Reports First Quarter 2022 Financial Results;
Results of operations · EX-99.1 to Form 8-K
QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS;
Results of operations · Other events · EX-99.1 to Form 8-K
QUEST DIAGNOSTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K